# US 2022/0033877 A1 · Methods of Administering 3,4-Diaminopyridine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033877 A1
- Document ID: US20220033877A1
- Status: Published application
- Kind: A1
- Application number: 17/503,190
- Filed: 2021-10-15
- Published: 2022-02-03
- Earliest claimed: 2011-06-30
- Assignees: Serb SA
- Applicants: Serb SA
- Inventors: Marvin R. GAROVOY; Peter E. HAROLDSEN; Donald G. MUSSON
- Web page: https://patentgrep.com/patent/US20220033877A1

## CPC

- C12Q 1/48: involving transferase
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 38/45: Transferases (2)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.

## Claims

### Claim 1

A method of treating a human patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) in need of treatment thereof comprising administering a total daily dose of 3,4-diaminopyridine (3,4-DAP), or an equivalent amount of a pharmaceutically acceptable salt thereof, to the patient,
wherein the patient has at least one N-acetyl transferase 2 (NAT2) fast allele, and the total daily dose is about 30 mg to about 240 mg of 3,4-DAP, or an equivalent amount of a pharmaceutically acceptable salt thereof, optionally provided as a series of divided doses, or
wherein the patient has two NAT2 slow alleles, each NAT2 slow allele is a NAT2*5, *6, *7, or *14 allele, and the total daily dose is about 7.5 mg to about 40 mg of 3,4-DAP, or an equivalent amount of a pharmaceutically acceptable salt thereof, optionally provided as a series of divided doses.

### Claim 2 (depends on 1)

The method of claim 1, wherein the NAT2 fast allele is a wild-type allele.

### Claim 3 (depends on 1)

The method of claim 1, wherein the two NAT2 slow alleles each comprise one or more of a 282T, 341C, 191A, 481T, 590A, or 857A mutation.

### Claim 4 (depends on 3)

The method of claim 3, wherein the two NAT2 slow alleles each comprise a 282T, a 341C mutation, or a 282T and a 341C mutation.

### Claim 5 (depends on 1)

The method of claim 1, wherein the about 30 mg to about 240 mg of 3,4-DAP is provided via an equivalent amount of 3,4-DAP phosphate salt.

### Claim 6 (depends on 1)

The method of claim 1, wherein the patient has at least one NAT2 fast allele, and the total daily dose is about 30 mg to about 100 mg of 3,4-DAP, or an equivalent amount of a pharmaceutically acceptable salt thereof

### Claim 7 (depends on 6)

The method of claim 6, wherein the total daily dose is provided via up to 5 divided doses per day.

### Claim 8 (depends on 7)

The method of claim 7, wherein the total daily dose is provided via 3 to 4 divided doses per day or 2 to 3 divided doses per day.

### Claim 9 (depends on 7)

The method of claim 7, wherein the divided dose is about 10 mg, about 15 mg, about 20 mg, about 25 mg, or about 30 mg of 3,4-DAP, or the equivalent amount of a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 6)

The method of claim 6, wherein the total daily dose is about 30 mg, about 50 mg, about 60 mg, about 80 mg, or about 100 mg of 3,4-DAP, or the equivalent amount of a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the about 7.5 mg to about 40 mg of 3,4-DAP is provided via an equivalent amount of 3,4-DAP phosphate salt.

### Claim 12 (depends on 1)

The method of claim 1, wherein the patient has two NAT2 slow alleles, and the total daily dose is about 15 mg to about 30 mg of 3,4-DAP, or the equivalent amount of a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the total daily dose is provided via 3 to 4 divided doses per day or 2 to 3 divided doses per day.

### Claim 14 (depends on 12)

The method of claim 12, wherein the total daily dose is about 15 mg or about 30 mg of 3,4-DAP, or the equivalent amount of a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the patient has two NAT2 slow alleles, and the total daily dose is about 7.5 mg to about 15 mg of 3,4-DAP, or the equivalent amount of a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the total daily dose is provided via 2 to 3 divided doses per day.

### Claim 17 (depends on 15)

The method of claim 15, wherein the total daily dose is about 7.5 mg of 3,4-DAP, or the equivalent amount of a pharmaceutically acceptable salt thereof.
